03.25.15
Following the launch of Kappa Bioscience AS Vitamin K2 MK-7 in the Australian market, ALS Pharmaceutical has been appointed the company’s preferred QC laboratory. ALS Pharmaceutical has received Kappa’s full analytical package on vitamin K2 MK-7 and has successfully implemented the technology.
ALS Pharmaceutical can offer consumer product testing on Vitamin K2 MK-7 for the local and international markets, which may include QC release testing and shelf life testing following customers or internationally recognized protocols.
“After Kappa’s successful application with the TGA and the introduction of Vitamin K2 MK-7 to the Australian market in June 2014, we have been overwhelmed with the positive response and adoption of Vitamin K2 MK-7 into local formulation. It is only fitting to ensure that a local, independent testing facility can provide reliable testing, ensuring both compliance and functionality of this key nutrient,” commented Peter Wisler, vice president of sales & marketing, Kappa Bioscience AS, Oslo, Norway.
Scott Colbourne, business manager ALS Pharmaceutical NSW, added, “extending our services to include the testing and verification of new ingredients such as Vitamin K2 MK-7 is an ongoing drive of ALS to stay closely connected to market needs and developments. The adoption of the internationally acknowledged testing method for Vitamin K2 MK-7 has given assurances of comparable results between international testing facilities.”
ALS Pharmaceutical can offer consumer product testing on Vitamin K2 MK-7 for the local and international markets, which may include QC release testing and shelf life testing following customers or internationally recognized protocols.
“After Kappa’s successful application with the TGA and the introduction of Vitamin K2 MK-7 to the Australian market in June 2014, we have been overwhelmed with the positive response and adoption of Vitamin K2 MK-7 into local formulation. It is only fitting to ensure that a local, independent testing facility can provide reliable testing, ensuring both compliance and functionality of this key nutrient,” commented Peter Wisler, vice president of sales & marketing, Kappa Bioscience AS, Oslo, Norway.
Scott Colbourne, business manager ALS Pharmaceutical NSW, added, “extending our services to include the testing and verification of new ingredients such as Vitamin K2 MK-7 is an ongoing drive of ALS to stay closely connected to market needs and developments. The adoption of the internationally acknowledged testing method for Vitamin K2 MK-7 has given assurances of comparable results between international testing facilities.”
